We had the opportunity to connect with some of the most forward-thinking biotech and AI-driven drug discovery companies such as Sergei Yakneen from Isomorphic Labs, Cyriac Roeding from Earli Inc., and the GenBio AI team, as well as visionary VCs like Molly Welch from Radical Ventures, Brentt Baltimore from Greycroft, and Janelle Teng from Bessemer Venture Partners.
The pace of change in our world is accelerating, and AI is at the center of it. We're proud to be part of the next wave of innovation, where machine learning meets molecular medicine.
Representing our team were Andrei Volgin (CEO) and Clay Moore (Lead Drug Discovery Scientist). We left energized, inspired, and ready to scale.
If you haven’t already, give us a follow to stay up to date on how we’re using AI to redesign the future of plants and medicine.
